why choose us

Clinical Trials Search

Showing 7,820 of 132,656 result(s)
Clinical Value of Plasma Humanin in Acute Kidney Injury

Status: Completed

Condition: Acute Kidney Injury

Interventions:

Date: 2023-10-07

Community-based Intervention to Prevent Intimate Partner Violence in Rural Southwest, Nigeria

Status: COMPLETED

Condition: Violence

Interventions: The intervention focused on creating awareness, challenging social norms, and promoting actions against violence.
To achieve these, the following

Date: 2023-10-07

Efficacy;Safety of ALTB-268 in Subjects w;Moderately to Severely Active UC Refractory to Biologics

Status: Completed

Condition: Ulcerative Colitis

Interventions: ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder.
All excipients

Date: 2023-10-06

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Status: NOT_YET_RECRUITING

Condition: Hypophosphatasia

Interventions: ALXN1850 will be administered via subcutaneous (SC) injection.

Date: 2023-10-06

Palliative Care Health Literacy Education and QOL Compared to Usual Care

Status: NOT_YET_RECRUITING

Condition: COPD

Interventions: Organizational Sponsored public domain educational videos

Date: 2023-10-06

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Status: Completed

Condition: Respiratory Syncytial Virus Infections

Interventions: Placebo

Date: 2023-10-06

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Status: NOT_YET_RECRUITING

Condition: Alzheimer's Disease

Interventions: GSK4527226 will be administered.

Date: 2023-10-06

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

Status: NOT_YET_RECRUITING

Condition: Hypophosphatasia

Interventions: Participants will receive a ALXN1850 via subcutaneous (SC) injection.

Date: 2023-10-06

A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

Status: NOT_YET_RECRUITING

Condition: Respiratory Syncytial Virus Infection

Interventions: Participants will receive tablets from Day 1 to Day 5

Date: 2023-10-06

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Status: Completed

Condition: Multiple Myeloma

Interventions: Days 1, 8 and 15, Cycles 1-8

Date: 2023-10-06